Abstract：
OBJECTIVE: There are inconsistent reports of an association between low cholesterol, use of lipid-lowering agents, and carcinogenesis. The purpose of this paper was to examine the relationship between cancer, lipids, statin use, and use of other lipid-lowering therapies.
METHODS: This comprehensive literature review incorporated article searches in electronic databases (Embase, PubMed, OVID) and reference lists of relevant articles, with the authors\' expertise in lipidology. This review considered seminal and novel research looking at the relationship between cholesterol, lipid-lowering therapies, and cancer.
RESULTS: Statin use has been reported to reduce the risk for incident cancer or progression of cancer; however, it is unknown whether this reduced risk of carcinogenesis is due to the pleotropic properties of statins or the effects of low cholesterol. The effect of ezetimibe on carcinogenesis has been regarded as neutral, despite earlier concerns of increased cancer risk with its use. Proprotein convertase subtilisin/kexin (PCSK)-9 monoclonal antibodies have been shown to have a neutral effect on carcinogenesis. Despite anti-cancer effects of fibrates in vitro, studies in humans have yielded inconsistent outcomes leaning toward protection against the development and progression of cancer.
CONCLUSIONS: Statins, fibrates, PCSK9 monoclonal antibodies, and ezetimibe have a neutral effect on cancer risk, and the first three may provide some protection. PSCK9 monoclonal antibodies have the potential to enhance the response to checkpoint inhibitor therapy for cancer. Further research is needed to determine which drugs can be issued in adjuvant therapy to improve outcomes in patients undergoing cancer treatment.
METHODS: This comprehensive literature review incorporated article searches in electronic databases (Embase, PubMed, OVID) and reference lists of relevant articles, with the authors\' expertise in lipidology. This review considered seminal and novel research looking at the relationship between cholesterol, lipid-lowering therapies, and cancer.
RESULTS: Statin use has been reported to reduce the risk for incident cancer or progression of cancer; however, it is unknown whether this reduced risk of carcinogenesis is due to the pleotropic properties of statins or the effects of low cholesterol. The effect of ezetimibe on carcinogenesis has been regarded as neutral, despite earlier concerns of increased cancer risk with its use. Proprotein convertase subtilisin/kexin (PCSK)-9 monoclonal antibodies have been shown to have a neutral effect on carcinogenesis. Despite anti-cancer effects of fibrates in vitro, studies in humans have yielded inconsistent outcomes leaning toward protection against the development and progression of cancer.
CONCLUSIONS: Statins, fibrates, PCSK9 monoclonal antibodies, and ezetimibe have a neutral effect on cancer risk, and the first three may provide some protection. PSCK9 monoclonal antibodies have the potential to enhance the response to checkpoint inhibitor therapy for cancer. Further research is needed to determine which drugs can be issued in adjuvant therapy to improve outcomes in patients undergoing cancer treatment.
摘要：
目的：关于低胆固醇、使用降脂药，和致癌作用。本文的目的是研究癌症之间的关系，脂质，他汀类药物的使用，和使用其他降脂疗法。
方法：这篇全面的文献综述将文章搜索纳入电子数据库(Embase，PubMed,OVID)和相关文章的参考列表，具有作者在血脂学方面的专业知识。这篇综述考虑了关于胆固醇之间关系的开创性和新颖的研究，降脂疗法，和癌症。
结果：据报道，使用他汀类药物可以降低癌症事件或癌症进展的风险；然而，目前尚不清楚这种降低致癌风险的原因是他汀类药物的多液特性还是低胆固醇的作用。依泽替米贝对癌变的影响被认为是中性的，尽管早些时候担心使用它会增加癌症风险。前蛋白转化酶枯草杆菌蛋白酶/kexin（PCSK）-9单克隆抗体已显示对致癌作用具有中性作用。尽管贝特类药物在体外具有抗癌作用，在人类中的研究得出的结果不一致，倾向于防止癌症的发展和进展。
结论：他汀类药物，贝多类,PCSK9单克隆抗体，依泽替米贝对癌症风险有中性影响，前三个可以提供一些保护。PSCK9单克隆抗体具有增强对癌症检查点抑制剂疗法的反应的潜力。需要进一步的研究来确定哪些药物可以在辅助治疗中使用，以改善接受癌症治疗的患者的预后。
方法：这篇全面的文献综述将文章搜索纳入电子数据库(Embase，PubMed,OVID)和相关文章的参考列表，具有作者在血脂学方面的专业知识。这篇综述考虑了关于胆固醇之间关系的开创性和新颖的研究，降脂疗法，和癌症。
结果：据报道，使用他汀类药物可以降低癌症事件或癌症进展的风险；然而，目前尚不清楚这种降低致癌风险的原因是他汀类药物的多液特性还是低胆固醇的作用。依泽替米贝对癌变的影响被认为是中性的，尽管早些时候担心使用它会增加癌症风险。前蛋白转化酶枯草杆菌蛋白酶/kexin（PCSK）-9单克隆抗体已显示对致癌作用具有中性作用。尽管贝特类药物在体外具有抗癌作用，在人类中的研究得出的结果不一致，倾向于防止癌症的发展和进展。
结论：他汀类药物，贝多类,PCSK9单克隆抗体，依泽替米贝对癌症风险有中性影响，前三个可以提供一些保护。PSCK9单克隆抗体具有增强对癌症检查点抑制剂疗法的反应的潜力。需要进一步的研究来确定哪些药物可以在辅助治疗中使用，以改善接受癌症治疗的患者的预后。
